Followers | 314 |
Posts | 10713 |
Boards Moderated | 16 |
Alias Born | 02/24/2010 |
Wednesday, October 27, 2021 1:33:55 PM
Recent HEPA News
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 02:02:26 PM
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:57 PM
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 • GlobeNewswire Inc. • 01/03/2024 10:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:24 PM
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat • GlobeNewswire Inc. • 11/10/2023 01:50:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/09/2023 05:15:08 AM
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules • GlobeNewswire Inc. • 09/29/2023 12:00:00 PM
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/21/2023 08:05:00 PM
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer • GlobeNewswire Inc. • 09/19/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 12:00:24 PM
- Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis • GlobeNewswire Inc. • 09/14/2023 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:40:33 PM
- Hepion Pharmaceuticals Announces Management Changes • GlobeNewswire Inc. • 09/06/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:41:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 08:39:46 PM
- Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 • GlobeNewswire Inc. • 06/15/2023 08:45:00 PM
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat • GlobeNewswire Inc. • 06/15/2023 12:22:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM